[ad_1]
A team of Israeli scientists belonging to a company called Accelerated Evolution Biotechnologies (AEBi) said to be at a stage where they can find a cure for cancer in one year. The therapy is being developed under the direction of Dr. Ilan Morad, CEO of AEBi.
Dan Aridor, president of AEBi, said in a statement: "We believe that we will propose in a year a complete treatment against cancer. Our cancer treatment will be effective from the first day, last a few weeks and will have no or few side effects at a cost well below that of most other treatments on the market. The treatment that the team is developing is called MuTaTo is the abbreviation for "multi-target toxin". The principle of this treatment is a combination of peptides or proteins targeting cancer and a toxin capable of killing cancer cells in a specific way.
In a statement, Dr. Morad said that this new treatment would soon be adapted to individual needs based on their type of cancer. According to statistics from the International Agency for Research on Cancer, every year in six deaths around the world are caused by cancer and 18.1 million new cases of cancer are detected each year in the world. This means that the new treatment, if it is proven, could benefit millions of experts, according to experts.
Dr. Morad explained that the team had completed animal testing with the new drug and treated laboratory mice with cancer. They found that the treatment affected and killed only the cancer cells and did not affect the healthy cells of the body. They also conducted in vitro laboratory tests with encouraging results. The team is ready to begin clinical trials on humans likely to be completed in the next few years. After approval, the drug could be used in cancer, says the team of researchers.
The team explains that their treatment has several components and that it attacks cancer cells in many ways. Dr. Morad said in a statement: "We have ensured that treatment will not be affected by mutations; the cancer cells can mutate in such a way that the targeted receptors are abandoned by the cancer. The likelihood of having multiple mutations that would simultaneously alter all target receptors decreases dramatically with the number of targets used … Instead of attacking the receptors one by one, attack the receptors three at a time.
Even cancer can not mutate three receptors at the same time, "he explained. He added that most existing anti-cancer drugs fail because they do not destroy cancer stem cells, which could lead to more cancer, and the cancer tends to return. "If the cancer is not completely annihilated, the remaining cells can begin to mutate, then the cancer reappears, but this time, it resists drugs," he said while talking about existing cancer drugs .
The experts took the news with a pinch of salt and wait for new peer-reviewed studies and evidence before they can believe such claims are true. Until then, the scientific community believes that if this treatment could actually work, it would be revolutionary in terms of cancer management and subsequent research.
Len Lichtenfeld, MD, chief medical officer of the CSA, said in a statement: "Needless to say, we all share the hope that they are right. Unfortunately, we must be aware that this is far from proven as an effective treatment for people with cancer, let alone cure. He added, "Our hopes are always on the side of new advances in the diagnosis and treatment of cancer. We live in a time when many exciting advances are affecting the care of cancer patients.
"We hope that this approach will also bear fruit and that it will be successful.At the same time, we must always keep in mind that the process of moving this treatment from the mouse to the Man is not always simple and without complications.
As experience has taught us time and time again, the gap between a successful mouse experiment and the effective and beneficial application of exciting laboratory concepts to help cancer patients at home. The patient's bedside is actually a long and perilous journey, strewn with unforeseen and unforeseen obstacles, "said Lichtenfeld warned.
[ad_2]
Source link
